^
    No biomarker
    Anal Carcinoma
    MIXE
    Sensitive: A2 - Guideline
    No biomarker
    Anal Carcinoma
    TPF
    Sensitive: A2 - Guideline
    No biomarker
    Anal Carcinoma
    pembrolizumab
    Sensitive: A2 - Guideline
    No biomarker
    Anal Carcinoma
    nivolumab
    Sensitive: A2 - Guideline
    No biomarker
    Anal Carcinoma
    FOLFOX
    Sensitive: A2 - Guideline
    No biomarker
    Anal Carcinoma
    carboplatin + paclitaxel
    Sensitive: A2 - Guideline
    No biomarker
    Anal Carcinoma
    FOLFCIS
    Sensitive: A2 - Guideline
    No biomarker
    Anal Carcinoma
    cisplatin + 5-fluorouracil
    Sensitive: A2 - Guideline
    No biomarker
    Anal Carcinoma
    mFOLFOX6
    Sensitive: A2 - Guideline
    No biomarker
    Anal Carcinoma
    capecitabine
    Sensitive: A2 - Guideline
    No biomarker
    Anal Carcinoma
    5-fluorouracil
    Sensitive: A2 - Guideline
    No biomarker
    Anal Carcinoma
    DCF
    Sensitive: A2 - Guideline
    No biomarker
    Anal Carcinoma
    cisplatin + docetaxel
    Sensitive: A2 - Guideline
    No biomarker
    Anal Carcinoma
    cisplatin + carboplatin
    Sensitive: A2 - Guideline
    No biomarker
    Anal Carcinoma
    cisplatin + 5-fluorouracil + capecitabine
    Sensitive: A2 - Guideline
    PD-L1 expression
    Anal Carcinoma
    pembrolizumab
    Sensitive: C1 - Off-label
    PD-L1 overexpression + TMB-H
    Anal Carcinoma
    EGFR inhibitor + Immunotherapy
    Sensitive: C3 – Early Trials
    CD163 expression
    Anal Carcinoma
    toripalimab
    Sensitive: C3 – Early Trials
    CD4 expression
    Anal Carcinoma
    toripalimab
    Sensitive: C3 – Early Trials
    PD-L1 expression
    Anal Carcinoma
    toripalimab
    Sensitive: C3 – Early Trials
    PD-L1 amplification + PD-L2 amplification + TMB-H
    Anal Carcinoma
    pembrolizumab
    Sensitive: C4 – Case Studies